Drugs / Unrelated Umbilical Cord Blood
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05584761 | Mar 2022 → Dec 2026 expected | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06109064 | Oct 2023 → Feb 2024 | myelodysplastic syndrome | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06105658 | Oct 2023 → Feb 2024 | acute myeloid leukemia | Anhui Provincial Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Unrelated Umbilical Cord Blood | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06109064 ↗ |
| Modality | Cell therapy | “unrelated umbilical cord blood stem cell microtransplantation” NCT05584761 ↗ |
| Route | Other | “Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion...” NCT05584761 ↗ |